Journal
MAYO CLINIC PROCEEDINGS
Volume 97, Issue 10, Pages 1904-1919Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2022.05.003
Keywords
-
Categories
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Lily USA, LLC
Ask authors/readers for more resources
Diabetic kidney disease is a leading cause of chronic kidney disease and kidney failure worldwide. While traditional treatments limited, the emergence of new classes of glucose-lowering agents has provided unprecedented opportunities to reduce the risk of kidney disease progression and death in DKD patients. Early detection and treatment are crucial for patient care.
Chronic kidney disease due to diabetes, or diabetic kidney disease (DKD), is a worldwide leading cause of chronic kidney disease and kidney failure and an increasingly important global public health issue. It is associated with poor quality of life, high burden of chronic diseases, and increased risk of premature death. Until recently, people with DKD had limited therapeutic options. Treatments have focused largely on glycemic and blood pressure control and renin-angiotensin system blockade, leaving patients with significant residual risk for progression of DKD. The availability of newer classes of glucose-lowering agents, namely, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, has changed the therapeutic landscape for these patients. These thera-pies have offered unprecedented opportunities to reduce the risk for progression of kidney disease and the risk of death that have led to recent updates to clinical guidelines. As such, the American Diabetes Association, the Kidney Disease: Improving Global Outcomes, and the European Association for the Study of Diabetes now recommend the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists for patients with DKD to provide both kidney and cardiovascular protective benefits. This review highlights the importance of early detection of DKD and summarizes the latest recommendations in the clinical guidelines on management of patients with DKD with hope of facilitating their uptake into everyday clinical practice. An integrated approach to patient care with a multidisciplinary focus can help achieve the necessary shift in clinical care of patients with DKD. (c) 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) center dot Mayo Clin Proc. 2022;97(10):1904-1919
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available